Paroxetine exposure during pregnancy and the risk of cardiac malformations: what is the evidence?
Bérard
Anick
A
Faculty of Pharmacy, University of Montreal, Montreal, Quebec, Canada. anick.berard@umontreal.ca
D000014:Abnormalities, Drug-Induced / Q000175:diagnosis / Q000453:epidemiology / Q000209:etiology*; D000328:Adult; D003627:Data Interpretation, Statistical; D019317:Evidence-Based Medicine; D005260:Female; D006330:Heart Defects, Congenital / Q000175:diagnosis / Q000453:epidemiology / Q000209:etiology*; D006801:Humans; D015201:Meta-Analysis as Topic; D017374:Paroxetine / Q000009:adverse effects*; D011247:Pregnancy; D011261:Pregnancy Trimester, First; D017367:Selective Serotonin Reuptake Inhibitors / Q000009:adverse effects*; D035501:Uncertainty
D017374:Paroxetine; D017367:Selective Serotonin Reuptake Inhibitors